

Supplementary Materials

Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer

Chih-Yu Chen ^{1,2}, Bing-Ru Wu ^{1,2}, Chia-Hung Chen ^{1,2}, Wen-Chien Cheng ^{1,2}, Wei-Chun Chen ^{1,3,4}, Wei-Chih Liao ^{1,2,4,*}, Chih-Yi Chen ⁵, Te-Chun Hsia ^{1,3,4}, Chih-Yen Tu ^{1,2}

¹ Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

² School of Medicine, China Medical University, Taichung, Taiwan

³ Department of Respiratory Therapy, China Medical University, Taichung, Taiwan

⁴ Hyperbaric oxygen therapy center, China Medical University Hospital, Taichung, Taiwan

⁵ Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan

* Correspondence: weichih.liao@gmail.com; Tel.: +886-4-2205-2121 EXT.4661 (W.-C.L.)




Figure S1. Disease-free survival curves of patients stratified by tumor size.

Table S1. Univariate analysis of factors associated with disease-free survival.

Parameter	Hazard ratio (95% CI)	P value
Age (≥ 65 y versus < 65)	1.144 (0.680-1.923)	0.612
Gender (male versus female)	0.900 (0.543-1.490)	0.681
Ever smoker (yes versus no)	0.884 (0.523-1.494)	0.645
Family history of cancer (yes versus no)	0.664 (0.345-1.278)	0.220
Performance status (ECOG 1 versus ECOG 0)	1.278 (0.776-2.104)	0.335
Clinical N2 (yes versus unsuspected)	1.560 (0.950-2.563)	0.079
Limited resection (yes versus anatomical)	1.797 (0.853-3.788)	0.123
VATS (yes versus open thoracotomy)	0.763 (0.463-1.258)	0.289
Tumor size (≤ 3 versus 3-5)	0.543 (0.328-0.900)	0.018
Histology (adenocarcinoma versus others)	1.158 (0.617-2.175)	0.648
Differentiation (poor versus others)	1.090 (0.651-1.825)	0.742
CEA (≥ 3 versus < 3)	1.796 (0.985-3.276)	0.056
Visceral pleural involvement (yes versus no)	1.366 (0.831-2.248)	0.219
Lymphovascular permeation (yes versus no)	1.182 (0.582-2.400)	0.643
Perineural invasion (yes versus no)	0.846 (0.417-1.718)	0.643
N2 ratio ($\geq 40\%$ versus $< 40\%$)	1.370 (0.814-2.304)	0.236
Central location (yes versus peripheral)	1.242 (0.750-2.055)	0.399
Lower lobe location (yes versus upper or middle)	0.988 (0.593-1.644)	0.961
Multiple N2 station (yes versus no)	1.220 (0.703-2.120)	0.480
Induction therapy (yes versus no)	0.568 (0.258-1.250)	0.160
Adjuvant therapy (yes versus no)	1.264 (0.617-2.591)	0.523
Postoperative radiotherapy (yes versus no)	0.648 (0.366-1.145)	0.135

Variables with P values of less than 0.2 were tested in multivariate analysis. ECOG, Eastern Cooperative Oncology Group; VATS, video-assisted thoracoscopic surgery; CEA, carcinoembryonic antigen.

Table S2. Multivariate analysis of factors associated with disease-free survival.

Parameter	Hazard ratio (95% CI)	P value
Clinical N2 (yes versus unsuspected)	2.525 (1.340-4.757)	0.004
Limited resection (yes versus anatomical)	1.442 (0.547-3.803)	0.459
Tumor size (≤ 3 versus 3-5)	0.451 (0.235-0.865)	0.017
CEA (≥ 3 versus < 3)	1.810 (0.914-3.588)	0.089
Induction therapy (yes versus no)	0.577 (0.185-1.800)	0.343
Postoperative radiotherapy (yes versus no)	0.889 (0.420-1.882)	0.758

CEA, carcinoembryonic antigen.